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Toward a Better Understanding of Prostate Cancer
Statistics
National health statistics document a decade-long increase in the incidence of
prostate cancer the likes of which have never been seen for this or any other cancer.
In 1986, 91 out of 100,000 US men were diagnosed with prostate cancer. ln 1994,
this rate had increased 60%, to 144 per 100,000. (1) This striking trend has
certainly not gone unnoticed by clinicians, policy-makers, or the public. The
widespread use of prostate specific antigen (PSA) screening has no doubt contributed
greatly to the rise in incidence. PSA-detected tumors tend to present earlier in their
natural history than tumors detected through other means. If this early detection
increases likelihood of successful treatment resulting in reduced mortality, then
screening clearly has conferred a benefit. If, however, patients with screen-detected
tumors are merely diagnosed earlier but have outcomes no different than those
detected through other means, the benefit of early detection is obviously
questionable.
Determining whether PSA screening leads to mortality benefits and answering other
related questions, such as what treatment approach is best for early-stage disease,
are difficult research propositions. Randomized clinical trials explicitly designed to
address these questions are now in the field but will not yield results for nearly a
decade. In the interim, patients, physicians, and health officials must return to
descriptive statistics to help inform their decision-making. In doing so they turn to
prostate cancer mortality rates. Time trends in these rates at the population level, as
well as comparisons of these rates across prospectively followed case series with
different diagnostic or treatment histories have been, and will continue to be,
undertaken as we wait for clinical trial data. If PSA screening is effective, the
increase in incidence observed in population data during the late 1980s and early
1990s will ultimately be followed by a decline in prostate cancer mortality rates.
Also, if aggressive surgical treatment of localized lesions differs in effectiveness from
a non-interventionist "watchful waiting" tactic, variation in prostate cancer mortality
rates should emerge across the historical cohorts managed under these alternative
approaches. Thus, prostate cancer cause-specific mortality statistics will be
prominent in the interim analyses completed over the next decade, addressing many
key questions in prostate cancer.
While cause-specific mortality rates are widely used and are generally perceived as
straight-forward statistics, there are a number of potential drawbacks to this
measure for prostate cancer. A research project underway at the Center for Research
in Medical Education and Health Care at Jefferson Medical College, in collaboration
with Saint Louis University's Prevention Research Center and the Centers for Disease
Control and Prevention, is exploring these issues. First, researchers are attempting
to determine whether the commonly used prostate cancer cause-specific mortality
rates based on underlying cause of death listed on death certificates accurately
estimate the mortality burden associated with the disease. Since 80% of prostate
cancer cases are over 65 and 17% are over age 80, (2) prostate cancer patients are
likely to be facing other chronic diseases as they fight their cancer. Under these
circumstances, attribution of a single underlying cause of death, even in the
presence of cancer, becomes more difficult. Preliminary findings presented by the
Jefferson team at the Society for Epidemiologic Research's 30th annual meeting this
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Spring in Edmonton, Canada suggest that cause-specific mortality rates may underreport prostate cancer's contribution to mortality by 15%.
The Jefferson research team is also investigating whether a key statistical
assumption, known as "independence of competing risks," commonly used in
calculating cause-specific mortality rates for patient case series, is appropriate when
series is comprised of older prostate cancer patients. In future projects, the Jefferson
group hopes to expand its work to determine the extent to which these potential
technical problems impact inferences drawn from these statistics and, if needed, to
develop easy tools for overcoming the problems in prostate cancer cause-specific
mortality rates.
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